NCT01624636View on ClinicalTrials.gov

Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Neovascular Age-related Macular Degeneration
Interventions
DRUG

Placebo

DRUG

LFG316

DRUG

LFG316

Trial Locations (3)

33880

Novartis Investigative Site, Winter Haven

44122

Novartis Investigative Site, Cleveland

85014

Novartis Investigative Site, Phoenix

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY

NCT01624636 - Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD). | Biotech Hunter | Biotech Hunter